Navidea biopharmaceuticals, inc. announces results of exploratory analysis completed on july 2, 2024

Columbus, ohio--(business wire)--navidea biopharmaceuticals, inc. (otc: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company's pivotal nav3-33 clinical trial titled “evaluation of tc 99m tilmanocept imaging for the early prediction of anti-tnfΑ therapy response in patients with moderate to severe active rheumatoid arthritis (r.
NAVB Ratings Summary
NAVB Quant Ranking